The substantial heterogeneity of AML, together with the limited selectivity of current DGK inhibitors, underscores the importance of identifying predictive biomarkers of sensitivity to DGKα or DGKζ blockade, which will be essential for defining responsive patient subgroups and guiding future clinical applications. This evidence concerns the gene DGKZ and acute myeloid leukemia.